FLEX Study

Clinical Trial Title MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry
Trial Status Open to Enrollment
Start Date 05/01/2023
Location hospitals
Trial Type Cancer - Adult Oncology
Specific Condition
Eligibility Criteria

Inclusion Criteria

  • Patients 18 years of age or older
  • Stage I, II, or III patients who receive MammaPrint, with or without BluePrint testing (male or female)
  • New primary lesion

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

  • Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria
  • Metastatic disease
  • Recurrent disease
  • Stage 0 disease

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.

IRB Number Central IRB
Principal Investigator Nathalie Johnson, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail oncologyresearch@lhs.org